Ineffectiveness of levamisole in systemic lupus erythematosus: a controlled trial

Abstract

Twenty-six patients with active systemic lupus erythematosus partially controlled by prednisone 30 mg daily or less were randomly selected to receive levamisole 150 mg weekly or placebo. Many patients showed increased disease activity over the 6-month trial period, and most required increased steroid dosage. Those on levamisole did no better than those on placebo.